Q1 2024 EPS Estimates for OptimizeRx Co. Decreased by William Blair (NASDAQ:OPRX)

OptimizeRx Co. (NASDAQ:OPRX) – Investment analysts at William Blair reduced their Q1 2024 EPS estimates for shares of OptimizeRx in a research report issued to clients and investors on Tuesday, April 16th. William Blair analyst R. Daniels now anticipates that the company will post earnings of ($0.34) per share for the quarter, down from their prior forecast of ($0.29). The consensus estimate for OptimizeRx’s current full-year earnings is ($0.59) per share. William Blair also issued estimates for OptimizeRx’s Q2 2024 earnings at ($0.21) EPS, Q3 2024 earnings at ($0.04) EPS, Q4 2024 earnings at $0.06 EPS and FY2024 earnings at ($0.51) EPS.

OPRX has been the topic of several other research reports. Stifel Nicolaus reissued a “buy” rating and set a $13.00 target price on shares of OptimizeRx in a research report on Monday, April 1st. Barclays initiated coverage on shares of OptimizeRx in a research report on Wednesday, January 3rd. They set an “equal weight” rating and a $15.00 target price on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $17.00 target price on shares of OptimizeRx in a research report on Monday, April 1st. Finally, JMP Securities reissued a “market outperform” rating and set a $15.00 target price on shares of OptimizeRx in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $15.86.

OptimizeRx Price Performance

NASDAQ:OPRX opened at $9.53 on Thursday. OptimizeRx has a twelve month low of $6.92 and a twelve month high of $16.65. The company’s 50 day moving average is $13.48 and its two-hundred day moving average is $11.97.

Institutional Trading of OptimizeRx

Several large investors have recently made changes to their positions in OPRX. UBS Group AG lifted its stake in shares of OptimizeRx by 290.0% in the 3rd quarter. UBS Group AG now owns 1,997 shares of the company’s stock valued at $29,000 after purchasing an additional 1,485 shares during the period. Nisa Investment Advisors LLC lifted its stake in shares of OptimizeRx by 215.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,142 shares of the company’s stock valued at $31,000 after purchasing an additional 1,462 shares during the period. Captrust Financial Advisors lifted its stake in shares of OptimizeRx by 248.8% in the 2nd quarter. Captrust Financial Advisors now owns 1,287 shares of the company’s stock valued at $35,000 after purchasing an additional 918 shares during the period. Quantbot Technologies LP acquired a new position in shares of OptimizeRx in the 3rd quarter valued at $49,000. Finally, Point72 Hong Kong Ltd acquired a new position in shares of OptimizeRx in the 1st quarter valued at $52,000. 76.47% of the stock is owned by hedge funds and other institutional investors.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.